Cara Therapeutics | CARA - Stock


Cara Therapeutics reported $900K in Stock for its fiscal quarter ending in March of 2025.





Stock Change Date
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Cara Therapeutics USD 900K 0 Mar/2025
Chugai Pharma JPY 276.85B 30.52B Dec/2025
Cipla INR 65.97B 4.37B Mar/2026
Clal Biotechnology ILS 4.44M 0 Mar/2021
CSL USD 6.47B 327M Jun/2025
Grifols EUR 3.56B 63.19M Dec/2024
Halozyme Therapeutics USD 137.14M 18.33M Jun/2026
J&J USD 15.14B 561M Jun/2026
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Pacira USD 134.57M 15.8M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
RedHill Biopharma USD 3.17M 482K Jun/2025
Supernus Pharmaceuticals USD 107.03M 3.74M Jun/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025